Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Insulin glulisine

Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal

DRUG

Insulin aspart

Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Paris

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY